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Background
Universal screening and brief intervention (SBI) for drug
use among primary care (PC) patients lacks efficacy but
the efficacy of SBI for low risk drug use is unknown. This
3-arm pilot study tested the efficacy of two brief inter-
ventions (BIs) for drug use compared to no BI in PC
patients with low risk drug use identified by screening.
Material and methods
We randomly assigned participants identified by screen-
ing with Alcohol Smoking and Substance Involvement
Screening Test (ASSIST) drug specific scores of 2 or 3
(consistent with low risk drug use) to: no BI, a brief
negotiated interview (BNI), or an adaptation of motiva-
tional interviewing (MOTIV). BNI was a 10-15 minute
structured interview conducted by health educators.
MOTIV was ¿45 minutes with an optional booster con-
ducted by trained master’s-level counselors. Primary
outcome was number of days use of self-identified main
drug in the past 30 as determined by validated calendar
method at 6 months. Analyses were performed using
negative binomial regression adjusted for baseline use
and main drug.
Results
Of 142 eligible adults, 61(43%) consented and were rando-
mized. Participant characteristics were: mean age 41; 54%
male; 77% black. Main drug was marijuana 70%, prescrip-
tion opioid 10%, cocaine 15%; 7% reported injection drug
use and mean days use of main drug (of 30) was 3.4. At
6 months, 93% completed follow-up and adjusted mean
days use of main drug were 6.4 (no BI) vs 2.1 (BNI) (inci-
dence rate ratio (IRR 0.33, 95% CI 0.15-0.74) and 2.3
(MOTIV) (IRR 0.36, 95% CI 0.15-0.85).
Conclusions
BI (both BNI and MOTIV) appears to have efficacy for
preventing an increase in drug use in primary care
patients with low risk use identified by screening. These
findings raise the potential that less severe patterns of
drug use in PC may be uniquely amenable to brief inter-
vention and warrant replication in a larger trial.
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